Q3 EPS Forecast for Dyne Therapeutics Decreased by Analyst

Key Points

• HC Wainwright cut Dyne Therapeutics’ Q3 2026 EPS forecast to a loss of $0.98 per share from $0.68, while projecting a $3.82-per-share loss for full-year 2026. The firm maintained its Buy rating and $50 price target.
• Dyne’s latest quarterly results missed expectations, with EPS of negative $1.08 versus the consensus estimate of negative $0.75, underscoring continued losses at the clinical-stage biotechnology company.
• Director Jason Rhodes sold 2.16 million shares for about $54 million under a pre-arranged Rule 10b5-1 plan, reducing his ownership by roughly 83%. Despite the insider sale, analysts hold a consensus “Moderate Buy” rating with an average target price of $34.42.

Dyne Therapeutics, Inc. (NASDAQ:DYN - Free Report) - Stock analysts at HC Wainwright reduced their Q3 2026 earnings per share estimates for shares of Dyne Therapeutics in a report issued on Monday, August 17th. HC Wainwright analyst A. Ghosh now anticipates that the company will post earnings of ($0.98) per share for the quarter, down from their previous estimate of ($0.68). HC Wainwright currently has a "Buy" rating and a $50.00 target price on the stock. The consensus estimate for Dyne Therapeutics' current full-year earnings is ($3.37) per share. HC Wainwright also issued estimates for Dyne Therapeutics' Q4 2026 earnings at ($1.01) EPS, FY2026 earnings at ($3.82) EPS, FY2027 earnings at ($3.28) EPS, FY2028 earnings at ($1.91) EPS, FY2029 earnings at ($0.49) EPS and FY2030 earnings at $1.28 EPS.

Several other research analysts also recently issued reports on DYN. Sanford C. Bernstein raised their price objective on shares of Dyne Therapeutics from $23.00 to $24.00 and gave the stock a "market perform" rating in a research report on Wednesday, May 13th. Wall Street Zen lowered Dyne Therapeutics from a "sell" rating to a "strong sell" rating in a report on Saturday, August 1st. Evercore set a $33.00 price objective on Dyne Therapeutics in a research note on Friday, May 15th. Morgan Stanley lowered their target price on Dyne Therapeutics from $47.00 to $45.00 and set an "overweight" rating on the stock in a research note on Friday, July 31st. Finally, Cantor Fitzgerald began coverage on Dyne Therapeutics in a research note on Thursday, July 23rd. They set an "overweight" rating for the company. Two investment analysts have rated the stock with a Strong Buy rating, ten have issued a Buy rating, two have issued a Hold rating and one has issued a Sell rating to the stock. According to MarketBeat, Dyne Therapeutics presently has a consensus rating of "Moderate Buy" and a consensus target price of $34.42.

Dyne Therapeutics Price Performance

DYN stock opened at $26.00 on Wednesday. The company has a current ratio of 12.02, a quick ratio of 12.02 and a debt-to-equity ratio of 0.28. The company has a market capitalization of $4.86 billion, a P/E ratio of -7.81 and a beta of 1.07. The business has a 50 day simple moving average of $23.18 and a 200-day simple moving average of $19.61. Dyne Therapeutics has a twelve month low of $11.65 and a twelve month high of $27.31.

Dyne Therapeutics (NASDAQ:DYN - Get Free Report) last released its quarterly earnings results on Thursday, July 30th. The company reported ($1.08) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.75) by ($0.33).

Hedge Funds Weigh In On Dyne Therapeutics

Several hedge funds and other institutional investors have recently bought and sold shares of DYN. Hilton Head Capital Partners LLC acquired a new stake in Dyne Therapeutics in the first quarter valued at $26,000. Strs Ohio acquired a new position in shares of Dyne Therapeutics during the 4th quarter worth $51,000. Allworth Financial LP purchased a new stake in shares of Dyne Therapeutics in the 2nd quarter worth about $62,000. Aster Capital Management DIFC Ltd purchased a new stake in shares of Dyne Therapeutics in the 4th quarter worth about $84,000. Finally, Steward Partners Investment Advisory LLC grew its stake in Dyne Therapeutics by 102.1% in the 4th quarter. Steward Partners Investment Advisory LLC now owns 4,880 shares of the company's stock valued at $95,000 after acquiring an additional 2,465 shares during the last quarter. 96.68% of the stock is owned by institutional investors and hedge funds.

Insider Transactions at Dyne Therapeutics

In other Dyne Therapeutics news, Director Jason P. Rhodes sold 2,160,516 shares of the stock in a transaction dated Friday, August 14th. The shares were sold at an average price of $25.00, for a total value of $54,012,900.00. Following the completion of the transaction, the director directly owned 428,946 shares of the company's stock, valued at approximately $10,723,650. This trade represents a 83.43% decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is accessible through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, CFO Erick Lucera sold 2,362 shares of Dyne Therapeutics stock in a transaction that occurred on Thursday, June 25th. The shares were sold at an average price of $20.37, for a total transaction of $48,113.94. Following the sale, the chief financial officer owned 121,563 shares of the company's stock, valued at approximately $2,476,238.31. The trade was a 1.91% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. In the last three months, insiders have purchased 6,500 shares of company stock worth $114,000 and have sold 4,139,196 shares worth $99,449,852. 9.46% of the stock is currently owned by insiders.

Dyne Therapeutics News Summary

Here are the key news stories impacting Dyne Therapeutics this week:

• Positive Sentiment: HC Wainwright maintained a Buy rating and a $50 price target, well above the recent trading range. The firm continues to project a potential shift to profitability by 2030, forecasting positive EPS of $1.28, despite near-term losses. HC Wainwright analyst coverage
• Neutral Sentiment: Institutional investors and hedge funds own approximately 96.7% of Dyne’s shares, while several funds recently increased their positions. Broader analyst sentiment remains favorable, with a consensus rating of “Moderate Buy” and an average price target of $34.42. Dyne institutional and analyst activity
• Negative Sentiment: HC Wainwright significantly reduced its EPS forecasts across 2026-2030. Estimates now call for losses of $3.82 per share in 2026, $3.28 in 2027, $1.91 in 2028 and $0.49 in 2029. Its Q3 and Q4 2026 loss estimates were also widened to $0.98 and $1.01 per share, respectively. The FY2030 profit forecast was cut from $2.26 to $1.28 per share, suggesting a slower path to profitability. Dyne earnings estimate revisions
• Negative Sentiment: Director Jason Rhodes sold a combined 2.59 million shares for approximately $65.2 million through pre-arranged Rule 10b5-1 plans, reducing his holdings by roughly 83% in one transaction and 36% in another. Although the sales were scheduled in advance, their size may pressure sentiment. Dyne director stock sale
• Negative Sentiment: Dyne previously reported quarterly EPS of negative $1.08, missing the consensus estimate of negative $0.75, reinforcing concerns about ongoing cash burn at the clinical-stage biotechnology company. Dyne quarterly earnings

Dyne Therapeutics Company Profile

Dyne Therapeutics is a clinical-stage biotechnology company specializing in the development of localized gene regulation therapies for serious rare diseases. The company's proprietary FORCE (Facilitated Orthogonal Receptor‐mediated Cargo Evaluation) platform is designed to enable targeted delivery of oligonucleotide and gene therapy modalities to skeletal and respiratory muscles. Dyne's lead programs focus on Duchenne muscular dystrophy (DMD), myotonic dystrophy type 1 (DM1) and facioscapulohumeral muscular dystrophy (FSHD), with preclinical and early clinical studies evaluating safety, tolerability and tissue specificity.

Since its founding in 2019 by Flagship Pioneering, Dyne has advanced multiple product candidates using its modular delivery approach, which couples engineered ligands with therapeutic payloads to improve uptake into muscle cells.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Continue following MarketBeat

Add MarketBeat as your preferred source on Google to see our latest stories in your feed.

Add As Preferred Source